Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for ...
Mersana Therapeutics: Promising Clinical Data and Strong Financial Position Justify Buy Rating
Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) and keeping the price target ...
Mersana falls after early-stage trial data for lead cancer therapy
Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...
Mersana Therapeutics, Inc.: Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...
kalkinemedia22h
Mercedes-Benz car sales decline in 2024 amidst challenging market conditions
Mercedes-Benz experienced a decline in core car sales throughout 2024, reflecting a challenging year for the auto industry, ...
kalkinemedia22h
Mersana Therapeutics (NASDAQ: MRSN) Announces Positive Initial Clinical Data for Emi-Le in Cancer Treatment
Announces Positive Initial Clinical Data for Emi-Le in Cancer Treatment ...
Mersana Shares Rise on Advances With Breast-Cancer Treatment
Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...
manilatimes1d
PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing
PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in microbiome ...
Mersana Therapeutics: ‘Positive’ results from Phase 1 emiltatug ledadotin trial
Mersana Therapeutics (MRSN) announced positive initial clinical data from the Phase 1 dose escalation and backfill cohorts for emiltatug ...
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ETCAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE ...
bovnews3d
Mersana Therapeutics Inc (MRSN) Stock Sees Market Value Hit $166.80 million: What Are the Implications?
Mersana Therapeutics Inc (MRSN) stock saw a decline, ending the day at $1.36 which represents a decrease of $-0.03 or -2.16% from the prior close of $1.39. The stock opened at $1.41 and touched a low ...
bovnews6d
Mersana Therapeutics Inc (MRSN) Stock Settles at $1.39: What’s Contributing to This Price Point?
Citigroup has recently resumed Mersana Therapeutics Inc (MRSN) stock to Buy rating, as announced on November 15, 2024, according to Finviz. Earlier, on March 19, 2024, JP Morgan had raised the stock ...